DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,112 filers reported holding DANAHER CORPORATION in Q4 2016. The put-call ratio across all filers is 0.26 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $983,068 | +6.6% | 3,934 | +6.5% | 0.03% | 0.0% |
Q1 2024 | $922,327 | +45.9% | 3,693 | +35.1% | 0.03% | +28.6% |
Q4 2023 | $632,252 | -17.0% | 2,733 | -11.0% | 0.02% | -27.6% |
Q3 2023 | $762,094 | +16.2% | 3,071 | +12.4% | 0.03% | +16.0% |
Q2 2023 | $656,080 | -4.0% | 2,733 | +0.8% | 0.02% | -10.7% |
Q1 2023 | $683,414 | -3.5% | 2,711 | +1.6% | 0.03% | -20.0% |
Q4 2022 | $708,285 | +242.2% | 2,668 | +232.7% | 0.04% | +218.2% |
Q3 2022 | $207,000 | +88.2% | 802 | +85.6% | 0.01% | +83.3% |
Q2 2022 | $110,000 | -65.3% | 432 | -60.0% | 0.01% | -53.8% |
Q1 2022 | $317,000 | -1.9% | 1,079 | +9.9% | 0.01% | -7.1% |
Q4 2021 | $323,000 | +13.7% | 982 | +5.5% | 0.01% | 0.0% |
Q3 2021 | $284,000 | +13.6% | 931 | 0.0% | 0.01% | +7.7% |
Q2 2021 | $250,000 | -15.3% | 931 | -29.1% | 0.01% | -27.8% |
Q1 2021 | $295,000 | -94.0% | 1,314 | -95.9% | 0.02% | -95.3% |
Q4 2019 | $4,955,000 | +1323.9% | 32,287 | +704.4% | 0.38% | +620.8% |
Q3 2017 | $348,000 | +4.2% | 4,014 | -0.1% | 0.05% | -1.9% |
Q2 2017 | $334,000 | +40.9% | 4,018 | +45.3% | 0.05% | +25.6% |
Q1 2017 | $237,000 | +7.7% | 2,765 | 0.0% | 0.04% | 0.0% |
Q4 2016 | $220,000 | +1.4% | 2,765 | 0.0% | 0.04% | -2.3% |
Q3 2016 | $217,000 | -14.9% | 2,765 | +9.5% | 0.04% | -17.0% |
Q2 2016 | $255,000 | -28.0% | 2,525 | -32.4% | 0.05% | -32.9% |
Q1 2016 | $354,000 | +1.7% | 3,733 | -0.2% | 0.08% | +3.9% |
Q4 2015 | $348,000 | -0.3% | 3,742 | -8.6% | 0.08% | -13.6% |
Q3 2015 | $349,000 | -10.5% | 4,092 | -10.1% | 0.09% | -5.4% |
Q2 2015 | $390,000 | -2.3% | 4,551 | -3.2% | 0.09% | +4.5% |
Q1 2015 | $399,000 | +3.9% | 4,701 | +5.1% | 0.09% | -7.3% |
Q4 2014 | $384,000 | +12.3% | 4,475 | -0.6% | 0.10% | +4.3% |
Q3 2014 | $342,000 | -3.4% | 4,500 | 0.0% | 0.09% | -4.2% |
Q2 2014 | $354,000 | +18.0% | 4,500 | +12.5% | 0.10% | +1.1% |
Q1 2014 | $300,000 | -2.9% | 4,000 | 0.0% | 0.10% | -8.7% |
Q4 2013 | $309,000 | +10.4% | 4,000 | -0.6% | 0.10% | -1.9% |
Q3 2013 | $280,000 | +7.7% | 4,024 | 0.0% | 0.11% | -11.7% |
Q2 2013 | $260,000 | – | 4,024 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |